Telomir Pharmaceuticals Secures Global Rights to Telomir-1 Through TELI Acquisition, Advances Toward Triple-Negative Breast Cancer Trial
核心洞察
Telomir Pharmaceuticals completed its acquisition of TELI Pharmaceuticals (搜索) on April 24, 2026, securing global rights to its lead candidate Telomir-1 (Telomir-Zn (搜索)) under a unified corporate structure.
The transaction provides $1.0 million in immediate funding with potential for up to $4.0 million in additional milestone-based contributions tied to clinical development progress.
The company has submitted an IND application to the FDA for Telomir-Zn (搜索) to treat advanced and metastatic triple-negative breast cancer (搜索), with plans for a Phase 1/2 clinical trial if cleared.
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced on April 24, 2026, the successful completion of its acquisition of TELI Pharmaceuticals (搜索), Inc., establishing global ownership rights to its lead therapeutic candidate Telomir-1 (Telomir-Zn (搜索)). The transaction consolidates worldwide development and commercialization rights under a single corporate structure, eliminating previous geographic fragmentation between North American and international rights.
Strategic Consolidation and Funding
The acquisition, approved by Telomir shareholders at the company's Annual Meeting on March 23, 2026, was structured as a stock-for-stock transaction that makes TELI a wholly owned subsidiary. Former TELI shareholders received Telomir common stock based on an independently determined exchange ratio, with shares subject to a six-month lock-up period.
"The closing of this transaction represents a defining milestone for Telomir," stated Erez Aminov, Chief Executive Officer. "By securing worldwide rights to Telomir-1 (Telomir-Zn (搜索)), we have established a globally unified platform as we advance toward clinical development."
The transaction includes immediate funding of $1.0 million at closing, with potential for up to an additional $4.0 million in milestone-based contributions from certain former TELI shareholders. These optional contributions are tied to key development milestones, including acceptance of an Investigational New Drug (IND) application and initiation of a Phase 1/2 clinical trial.
Clinical Development Progress
The acquisition follows Telomir's recent submission of an IND application to the U.S. Food and Drug Administration (FDA) for Telomir-Zn (搜索) targeting advanced and metastatic triple-negative breast cancer (搜索). If the IND receives clearance, the company plans to initiate a Phase 1/2 clinical trial evaluating Telomir-Zn as an oral monotherapy in patients with advanced or metastatic triple-negative breast cancer.
Therapeutic Mechanism and Preclinical Activity
Telomir-1 (Telomir-Zn (搜索)) is an investigational small-molecule therapeutic designed to target epigenetic and metabolic mechanisms implicated in cancer (搜索), aging, and degenerative diseases. According to the company, the candidate has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, epigenetic regulation, mitochondrial function, and genomic stability.
The biotechnology company focuses on developing therapeutics that target epigenetic and metabolic drivers of cancer (搜索) and age-related diseases, positioning Telomir-1 as its lead program in this therapeutic approach.
Strategic Positioning
Aminov noted that the unified global platform positions the company to progress into clinical development while maintaining flexibility to evaluate global partnership opportunities. The consolidation provides Telomir with full control over development and potential commercialization across major international markets, addressing the previous fragmentation of rights that existed before the transaction.